LP
PTGX icon

LMR Partners’s Protagonist Therapeutics PTGX Stock Holding History

LMR Partners’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.25M Sell
30,850
-9,150
-23% -$810K 0.01% 756
2025
Q4 		$3.49M Buy
+40,000
New +$3.27M 0.01% 673
2018
Q3 		– Sell
-31,228
Closed -$210K – 470
2018
Q2 		$210K Buy
+31,228
New +$240K 0.01% 409

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

LMR Partners's PTGX Position: Q1 2026 in Review

LMR Partners reduced its Protagonist Therapeutics (PTGX) stake by 23% in Q1 2026, selling an estimated $810K and leaving 30,850 shares worth $3.25M. The position accounts for 0.01% of the portfolio, ranked #756.

LMR Partners first reported a position in PTGX in Q2 2018 and has held it in 3 quarters since. The position peaked at $3.49M in Q4 2025. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • LMR Partners held 30,850 shares of Protagonist Therapeutics worth $3.25M as of Q1 2026.
  • LMR Partners sold 9,150 Protagonist Therapeutics shares in Q1 2026, an estimated $810K.
  • Protagonist Therapeutics made up 0.01% of LMR Partners's portfolio in Q1 2026, its #756 holding.
  • LMR Partners first reported a position in Protagonist Therapeutics in Q2 2018 and has held it in 3 quarters since.
  • LMR Partners's Protagonist Therapeutics position peaked at $3.49M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.